2017: Year in Review

Written by Igor Fisch, PhD on January 2018

January 4, 2018 An idea is something that won’t work unless you do. – Thomas Edison As I look around our new corporate headquarters and laboratories, I am reminded of how far Selexis has come since we began our work in cell line generation more than 15 years ago. 2017 was certainly no exception and […]

Read More

Biosimilarity: It starts by selecting the right manufacturing cell line

Written by Igor Fisch, PhD on December 2017

December 21, 2017 The recombinant therapeutic patent cliff has ushered in a new promise for access to less expensive biologic therapies, called biosimilars. Just recently, in fact, the US Food & Drug Administration approved the first biosimilar for the treatment of certain breast and stomach cancers, known as Ogivri (trastuzumab-dkst) – which is a biosimilar […]

Read More

CHO Cells Are Here to Stay?

Written by Igor Fisch, PhD on November 2017

November 30, 2017 I have recently read a couple of industry articles around cell line development that claim the Chinese hamster ovary (CHO) cell line is not the future of biomanufacturing and that alternative non-mammalian platforms, such as fungal, algae and plant systems, will offer the low-cost solutions that CHO cannot. Make no mistake, it […]

Read More